Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Total
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Deficit
Beginning balance (in shares) at Apr. 30, 2021   25,066,297      
Beginning balance at Apr. 30, 2021 $ 49,090,474 $ 25,067 $ 109,040,824 $ (1,817,414) $ (58,158,003)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 1,264,870   1,264,870    
Common stock issued for vested restricted stock units (in shares)   34,989      
Common stock issued for vested restricted stock units 0 $ 35 (35)    
Common stock issued for stock options exercised for cash (in shares)   16,752      
Common stock issued for stock options exercised for cash 56,034 $ 17 56,017    
Common stock issued for cashless stock options exercised (in shares)   30,156      
Common stock issued for cashless stock options exercised 0 $ 30 (30)    
Amortization of warrant based cost 27,583   27,583    
Warrants issued for deferred financing costs related to Credit Facility 137,500   137,500    
Net loss (3,723,146)       (3,723,146)
Ending balance (in shares) at Oct. 31, 2021   25,148,194      
Ending balance at Oct. 31, 2021 46,853,315 $ 25,149 110,526,729 (1,817,414) (61,881,149)
Beginning balance (in shares) at Jul. 31, 2021   25,087,051      
Beginning balance at Jul. 31, 2021 48,796,304 $ 25,088 109,617,521 (1,817,414) (59,028,891)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 722,158   722,158    
Common stock issued for vested restricted stock units (in shares)   19,332      
Common stock issued for vested restricted stock units 0 $ 19 (19)    
Common stock issued for stock options exercised for cash (in shares)   11,655      
Common stock issued for stock options exercised for cash 33,486 $ 12 33,474    
Common stock issued for cashless stock options exercised (in shares)   30,156      
Common stock issued for cashless stock options exercised 0 $ 30 (30)    
Amortization of warrant based cost 16,125   16,125    
Warrants issued for deferred financing costs related to Credit Facility 137,500   137,500    
Net loss (2,852,258)       (2,852,258)
Ending balance (in shares) at Oct. 31, 2021   25,148,194      
Ending balance at Oct. 31, 2021 $ 46,853,315 $ 25,149 110,526,729 (1,817,414) (61,881,149)
Beginning balance (in shares) at Apr. 30, 2022 25,202,278 25,357,764      
Beginning balance at Apr. 30, 2022 $ 42,545,724 $ 25,358 112,081,564 (1,817,414) (67,743,784)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 504,666   504,666    
Common stock issued for vested restricted stock units (in shares)   66,245      
Common stock issued for vested restricted stock units 0 $ 66 (66)    
Common stock issued for services (in shares)   25,000      
Common stock issued for services 24,500 $ 25 24,475    
Common stock issued for equity raise, net of underwriter costs (in shares)   11,840      
Common stock issued for equity raise, net of underwriter costs 9,535 $ 12 9,523    
Amortization of warrant based cost 14,000   14,000    
Net loss $ (6,008,611)       (6,008,611)
Ending balance (in shares) at Oct. 31, 2022 25,305,363 25,460,849      
Ending balance at Oct. 31, 2022 $ 37,089,814 $ 25,461 112,634,162 (1,817,414) (73,752,395)
Beginning balance (in shares) at Jul. 31, 2022   25,357,764      
Beginning balance at Jul. 31, 2022 38,884,083 $ 25,358 112,134,894 (1,817,414) (71,458,755)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 458,336   458,336    
Common stock issued for vested restricted stock units (in shares)   66,245      
Common stock issued for vested restricted stock units 0 $ 66 (66)    
Common stock issued for services (in shares)   25,000      
Common stock issued for services 24,500 $ 25 24,475    
Common stock issued for equity raise, net of underwriter costs (in shares)   11,840      
Common stock issued for equity raise, net of underwriter costs 9,535 $ 12 9,523    
Amortization of warrant based cost 7,000   7,000    
Net loss $ (2,293,640)       (2,293,640)
Ending balance (in shares) at Oct. 31, 2022 25,305,363 25,460,849      
Ending balance at Oct. 31, 2022 $ 37,089,814 $ 25,461 $ 112,634,162 $ (1,817,414) $ (73,752,395)